Front-line use of ibrutinib for CLL in a real-world setting
What does the future treatment landscape of myeloma look like?
Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel
Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and ADCs
Why global collaborations are key in multiple myeloma